Aton Ra Partners Kymera Therapeutics, Inc. Transaction History

Aton Ra Partners

$50.1 Million
Q4 2023

A detailed history of Aton Ra Partners transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Aton Ra Partners holds 16,808 shares of KYMR stock, worth $685,598. This represents 0.85% of its overall portfolio holdings.

Number of Shares

16,808

Previous 19,172 12.33%

Holding current value

$685,598

Previous $266,000 60.53%

% of portfolio

0.85%

Previous 0.56%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$10.97 - $26.84 $25,933 - $63,449	-2,364 Reduced 12.33%	16,808 $427,000
Q3 2023 Oct 25, 2023	SELL	$13.9 - $23.88 $38,572 - $66,267	-2,775 Reduced 12.64%	19,172 $266,000
Q2 2023 Jul 18, 2023	SELL	$22.4 - $34.92 $41,036 - $63,973	-1,832 Reduced 7.7%	21,947 $504,000
Q1 2023 May 05, 2023	SELL	$24.84 - $38.75 $83,114 - $129,657	-3,346 Reduced 12.34%	23,779 $704,000
Q4 2022 Feb 02, 2023	SELL	$19.57 - $30.92 $143,585 - $226,860	-7,337 Reduced 21.29%	27,125 $677,000
Q3 2022 Nov 14, 2022	SELL	$20.91 - $34.27 $2,801 - $4,592	-134 Reduced 0.39%	34,462 $750,000
Q2 2022 Aug 15, 2022	SELL	$14.13 - $42.55 $245,409 - $739,008	-17,368 Reduced 33.42%	34,596 $681,000
Q1 2022 May 16, 2022	BUY	$35.3 - $64.68 $149,495 - $273,919	4,235 Added 8.87%	51,964 $2.2 Million
Q4 2021 Feb 14, 2022	BUY	$49.91 - $65.56 $880,462 - $1.16 Million	17,641 Added 58.63%	47,729 $3.03 Million
Q3 2021 Nov 15, 2021	BUY	$47.8 - $66.66 $149,614 - $208,645	3,130 Added 11.61%	30,088 $1.77 Million
Q2 2021 Aug 12, 2021	BUY	$31.08 - $51.95 $837,854 - $1.4 Million	26,958 New	26,958 $1.31 Million

Others Institutions Holding KYMR

# of Institutions

184

Shares Held

64.4M

Call Options Held

50.6K

Put Options Held

81.7K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.23B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

News

Stay updated on Aton Ra Partners with notifications on news.

Account